FYI - For Your Innovation

• Private Money Rises: Tether, Bitcoin, And The Genius Act

  Since inception, ARK has researched and published thoughts on the cryptocurrency ecosystem within Big Ideas and through articles, whitepapers, monthly Bitcoin reports and podcasts. Now, in coordination with Bitcoin Park, ARK is pleased to host a monthly conversation with leaders in the Bitcoin space, to discuss everything happening in the rapidly-changing and still nascent Bitcoin ecosystem. Published through the For Your Innovation podcast channels, this monthly series aims to be informative and enlightening, including experts with diverse viewpoints.Guests on this month’s Bitcoin Brainstorm include:Cathie Wood: Founder, CEO and CIO, ARK InvestLorenzo Valente: Director of Research, Digital Assets, ARK InvestPaolo Ardoino: CEO, TetherDr. Arthur Laffer: American EconomistRod Roudi: Co-Founder, Bitcoin ParkKey Points From This Episode: 00:00:00 Introduction00:01:04 The origin of Bitcoin and stablecoins00:04:22 Understanding Tether (USDT)00:10:33 USDT's global growth amid pandemic shifts00:12:15 Dr. Laffer’s history of private money00:17:32 Understanding the USDT mechanics of issuance, reserves, and redemptions00:23:14 Transparency, audits and regulation00:30:26 Challenges of value stability vs dollar peg00:35:20 Gold-backed solutions and the alloy product00:38:58 The role of stablecoins in developed markets00:44:40 Potential competition00:46:00 Commodity trade and global adoption trends00:51:00 Emerging markets00:53:50 Dollar dominance vs local stablecoins01:08:01 Vision for the future Links Mentioned in this Episode: Learn more about Bitcoin Park: bitcoinpark.com

  --------  

  1:08:54

  --------

  1:08:54
• FDA Regulation On Gene Therapy | The Brainstorm EP 96

  In this episode of the Brainstorm, Sam, Nick, and Multiomics Research Analyst, Shea Wihlborg, dive into the complexities of the FDA's recent decisions and their implications for gene therapy. They discuss the controversial halt of a Duchenne muscular dystrophy treatment, the role of AI in drug discovery, and the exciting future of genomics. If you know ARK, then you probably know about our long-term research projections, like estimating where we will be 5-10 years from now! But just because we are long-term investors, doesn’t mean we don’t have strong views and opinions on breaking news. In fact, we discuss and debate this every day. So now we’re sharing some of these internal discussions with you in our new video series, “The Brainstorm”, a co-production from ARK and Public.com. Tune in every week as we react to the latest in innovation. Here and there we’ll be joined by special guests, but ultimately this is our chance to join the conversation and share ARK’s quick takes on what’s going on in tech today.Key Points From This Episode:Discussion on the FDA's recent halt of a Duchenne muscular dystrophy treatment due to safety concerns.Exploration of the role of AI in improving drug discovery and clinical trials.Insights into the future of gene therapies for both rare and common diseases.The potential impact of regulatory changes on innovation in the biotech industry.For more updates on Public.com:Website: https://public.com/YouTube: @publicinvestX: https://twitter.com/public

  --------  

  15:54

  --------

  15:54
• Coinbase's New App: BASE | The Brainstorm EP 95

  In this episode of the Brainstorm, Sam, Nick, and Director of Research, Digital Assets, Lorenzo Valente, dive into the latest developments from Coinbase, focusing on the launch of the BASE app. They explore the three pillars of the BASE ecosystem: BASE chain, BASE build, and BASE app, and discuss how these innovations aim to enhance user experience with faster transactions, developer tools, and a reimagined non-custodial wallet. The conversation also touches on the integration of social media and financial markets, the evolving landscape of crypto trading, and the potential for new user engagement.If you know ARK, then you probably know about our long-term research projections, like estimating where we will be 5-10 years from now! But just because we are long-term investors, doesn’t mean we don’t have strong views and opinions on breaking news. In fact, we discuss and debate this every day. So now we’re sharing some of these internal discussions with you in our new video series, “The Brainstorm”, a co-production from ARK and Public.com. Tune in every week as we react to the latest in innovation. Here and there we’ll be joined by special guests, but ultimately this is our chance to join the conversation and share ARK’s quick takes on what’s going on in tech today.Key Points From This Episode:Coinbase launched the BASE app, featuring a faster BASE chain, developer tools, and a rebranded non-custodial wallet.The BASE app integrates NFT minting and decentralized social feeds, creating a hybrid platform for trading and social interaction.There’s potential for BASE to compete with platforms like Robinhood by offering a more crypto-native experience.For more updates on Public.com:Website: https://public.com/YouTube: @publicinvestX: https://twitter.com/public

  --------  

  16:32

  --------

  16:32
• Pharmaceutical Superintelligence With Alex Zhavoronkov

  In this episode of FYI, Chief Futurist, Brett Winton, and Analyst Nemo Marjanovic speak with Alex Zhavoronkov, founder and CEO of Insilico Medicine. Together, they explore the promise of artificial intelligence in transforming the drug discovery process—cutting years off timelines and dramatically reducing costs. Alex shares Insilico’s journey from algorithm-first beginnings to a full-stack AI-driven biotech company, highlighting their unique “pan flute” model approach to drug development and the vision of building a “pharmaceutical superintelligence.” The discussion touches on Insilico’s clinical progress, including a molecule that recently completed a Phase 2 trial, and how its generative platforms are helping to tackle complex diseases with a focus on longevity.Key Points From This Episode:00:00:00 AI's promise in streamlining the drug discovery process00:03:06 The economics of preclinical development and AI’s role in optimization00:04:43 Potential cost and timeline reductions: $2.4B down to $600M, 13 years to 800:07:39 Comparing Insilico’s approach to peers like Recursion and AbSci00:10:35 Literature-driven vs. biology-driven models in drug discovery00:13:07 Why a dominant AI platform could reshape biotech industry consolidation00:14:57 Why biologics may be more suited to AI than small molecules00:17:35 Alex Zhavoronkov on founding Insilico and his mission in longevity science00:21:00 From algorithms to real drugs: Insilico’s transition to clinical development00:23:15 Managing the pace of AI progress vs. the slow cycle of experimental validation00:27:10 How “pharmaceutical superintelligence” enables prompt-to-drug workflows00:32:26 Validation, trust, and why Insilico runs on both old and frontier models00:39:22 The “pan flute” architecture: stacking specialized models with reinforcement learning00:42:36 Building and training a unified multimodal model for chemistry and biology00:45:32 Public data, clean pipelines, and Insilico’s automated validation lab00:50:47 The business model behind Insilico: selling candidates and licensing platforms00:55:12 Why pharma buyers care more about data room quality than pricing01:00:25 On profitability, licensing success, and the dream of a self-sustaining AI biotech01:01:38 Longevity and the search for fundamental mechanisms of aging

  --------  

  1:30:32

  --------

  1:30:32
• From Customer Service To The Classroom – AI Agents Are Coming For It All With Alan Bekker

  Brett Winton and ARK analyst Jozef Soja dive deep into the rapidly evolving world of AI agents—software entities that are increasingly automating enterprise functions like customer support. They explore why AI agents are gaining traction, how they’re priced, and the potential for a new kind of agent-versus-agent arms race between companies and consumers. Later in the episode, they’re joined by Dr. Alan Bekker, founder of eSelf.ai and former Head of Conversational AI at Snap, who shares his journey from building voice agents for call centers to launching a real-time, face-to-face AI tutoring platform. Alan offers insights into how the rise of large language models (LLM) is reshaping education, what makes a great AI tutor, and why a visual, embodied presence is crucial for learning.Key Points From This Episode:00:00:00 What enterprise AI agents actually do and how companies like Salesforce are pricing them00:03:41 Why $2 per AI conversation may already undercut human support costs00:05:04 The Return On Investment (ROI) model behind agent adoption and enterprise productivity00:06:41 Why agent-based software may retain higher pricing power than other AI tools00:09:11 The coming arms race: AI agents negotiating with other AI agents00:12:30 Scaling demand for customer service with intelligent automation00:15:04 Vertical vs. horizontal Software as a Service (SaaS) in the AI agent ecosystem00:16:43 AI’s impact across the software stack—SaaS, Platform as a Service (PaaS) , and Infrastructure as a Service (IaaS)00:17:56 Why building your own AI apps may soon be cheaper than onboarding SaaS00:20:01 ARK's  internal hackathon and how non-engineers are becoming developers00:20:29 Guest: Dr. Alan Bekker joins to discuss the evolution of conversational AI00:22:04 The journey from decision trees to LLMs: Lessons from Snap’s AI team00:27:32 Seeing GPT’s impact from inside: OpenAI’s early partner outreach00:31:47 Why face-to-face AI tutors found strong product-market fit in education00:33:59 eSelf’s go-to-market strategy: Partnering with publishers as a business to business to consumer (B2B2C) wedge00:36:24 Pricing real-time AI tutoring tools in a margin-conscious market00:40:00 Business to consumer (B2C) aspirations: Moving toward a direct-to-student tutoring product00:44:56 What’s still missing for real-time AI to match human-level teaching00:48:03 The psychological impact of avatars: Building trust through embodied agents00:51:43 Why personalization—not just LLM knowledge—matters in tutoring00:54:20 Democratizing learning: LLMs as the end of expert-driven education

  --------  

  55:31

  --------

  55:31

Meer Zaken en persoonlijke financiën podcasts

Trending Zaken en persoonlijke financiën -podcasts

Over FYI - For Your Innovation

FYI - For Your Innovation: Podcasts in familie